Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** Treatment of ACS, including unstable angina, non-ST-elevation MI (NSTEMI), and ST-elevation MI (STEMI).
* **Post-MI:** To reduce the rate of cardiovascular death, MI, and stroke in patients with a history of MI at least one year prior.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months. In some cases, it may be continued beyond 12 months, especially in patients with ongoing risk.
* **Post-MI (at least 1 year after MI):**
* **Maintenance Dose:** 60 mg orally twice daily. This is typically used in patients who have completed at least 12 months of ticagrelor 90 mg twice daily or another P2Y12 inhibitor and are at high risk for occlusive events.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Safety and efficacy in severe hepatic impairment have not been studied.
* **Renal Impairment:** No dose adjustment is required for mild to moderate renal impairment. In severe renal impairment, caution is advised.
* **Concomitant Medications:**
* **CYP3A4 Inhibitors/Inducers:** Avoid strong CYP3A4 inhibitors/inducers. Moderate inhibitors may require caution.
* **Aspirin:** Generally co-administered with aspirin. Dose of aspirin may need adjustment if >100 mg daily is used, as this increases bleeding risk.
* **Other Antithrombotics:** Use with caution.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Common:** Dyspnea, bradyarrhythmia, ventricular pauses, increased serum creatinine, increased uric acid.
* **Serious:** Bleeding (major, minor, fatal), hypersensitivity reactions.
* **Important:** Ticagrelor can cause significant bleeding. The risk is higher in patients with recent transient ischemic attack (TIA) or stroke.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor inhibits CYP3A4, increasing the plasma concentrations of drugs metabolized by this enzyme (e.g., simvastatin, atorvastatin, certain calcium channel blockers). Concurrent use of statins at higher doses should be avoided.
* **Strong CYP3A4 Inducers:** (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure.
* **Strong CYP3A4 Inhibitors:** (e.g., ketoconazole, clarithromycin, ritonavir) may increase ticagrelor exposure.
* **Other Antithrombotics:** Increased risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor renal function and uric acid levels.
* Assess for dyspnea.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel.
* The 60 mg twice daily dose is for long-term maintenance in specific post-MI patients at high risk.
* Dyspnea is a common side effect and is generally not a contraindication to continue therapy unless severe.
* Discontinuation of ticagrelor should be carefully considered due to the increased risk of thrombotic events.
***
*This information is intended for healthcare professionals. Please consult the most current prescribing information for complete details and to verify dosages and guidelines.*
